Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas L. Walsh is active.

Publication


Featured researches published by Thomas L. Walsh.


BMC Infectious Diseases | 2016

Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients

Thomas L. Walsh; Lynn Chan; Chelsea I. Konopka; Michael J. Burkitt; Matthew A. Moffa; Derek N. Bremmer; Monika Murillo; Courtney Watson; Noreen H. Chan-Tompkins

BackgroundSkin and soft tissue infections (SSTIs) are a leading cause for hospitalizations in the United States. Few studies have addressed the appropriateness of antibiotic therapy in the management of SSTIs without complicating factors. We aimed to determine the appropriateness of antibiotic treatment duration for hospitalized adult patients with uncomplicated SSTIs.MethodsThis was a retrospective analysis performed at two academic medical centers in Pittsburgh, Pennsylvania on patients aged 18 years and older with primary ICD-9 code for SSTIs admitted August 1st, 2014–March 31st, 2015. The primary outcome was the appropriateness of antibiotic treatment duration for uncomplicated SSTIs. Secondary objectives included the appropriateness of antibiotic agent spectrum, duration of inpatient length of stay (LOS), utilization of blood cultures and advanced imaging modalities, and re-hospitalization for SSTI within 30 days of discharge from the index admission.ResultsA total of 163 episodes were included in the cohort. The mean duration of total antibiotic therapy was 12.6 days. Appropriate duration was defined as receipt of total antibiotic duration of less than 10 days and occurred in 20.2% of patients. Twenty eight percent of patients received antibiotics for greater than 14 days. Seventy three (44.8%) patients received greater than 24 h of inappropriate extended spectrum gram-negative coverage; 65 (39.9%) received anaerobic coverage.ConclusionsIn the majority of patients, treatment duration was excessive. Inappropriate broad spectrum antibiotic selection was utilized with regularity for SSTIs without complicating factors. The management of uncomplicated SSTIs represents a significant opportunity for antimicrobial stewardship.


Mayo Clinic Proceedings: Innovations, Quality & Outcomes | 2017

Effect of Antimicrobial Stewardship Program Guidance on the Management of Uncomplicated Skin and Soft Tissue Infections in Hospitalized Adults

Thomas L. Walsh; Derek N. Bremmer; Matthew A. Moffa; Noreen H. Chan-Tompkins; Monika Murillo; Lynn Chan; Michael J. Burkitt; Chelsea I. Konopka; Courtney Watson; Tamara Trienski

Objective To assess the effect of an antimicrobial stewardship program (ASP)–bundled initiative on the appropriate use of antibiotics for uncomplicated skin and soft tissue infections (uSSTIs) at 2 academic medical centers in Pittsburgh, Pennsylvania. Patients and Methods A retrospective preintervention and postintervention study was conducted to compare management of patients admitted with uSSTIs before and after the implementation of the bundled initiative. The preintervention period was from August 1, 2014, through March 31, 2015, and the postintervention period was from August 1, 2015, through March 31, 2016. Results A total of 160 patients were included in the preintervention cohort, and 163 were included in the postintervention cohort. Compared with the preintervention group, the mean duration of therapy decreased (12.5 days vs 8.8 days; P<.001) and an appropriate duration of less than 10 days increased in more patients (20.6% [33 of 160] vs 68.7% [112 of 163]; P<.001) in the postintervention period. Fewer patients were exposed to antimicrobials with extended gram-negative (44.4% [71 of 160] vs 9.2% [15 of 163]; P<.001), anaerobic (39.4% [63 of 160] vs 9.8% [16 of 163]; P<.001), and antipseudomonal (16.3% [26 of 160] vs 1.8% [3 of 163]; P<.001) coverage. The mean length of stay decreased from 3.6 to 2.2 days (P<.001) without an increase in 30-day readmissions (6.3% [10 of 160] vs 4.9% [8 of 163]; P=.64). The ASP made recommendations for 125 patients, and 96% were accepted. Conclusion Implementation of an ASP-bundled approach aimed at optimizing antibiotic therapy in the management of uSSTIs led to shorter durations of narrow-spectrum therapy as well as shorter hospital length of stay without adversely affecting hospital readmissions.


Medical Clinics of North America | 2018

Role of Technology in Antimicrobial Stewardship

Derek N. Bremmer; Tamara L. Trienski; Thomas L. Walsh; Matthew A. Moffa

Because of the increasing plague of antimicrobial resistance and antibiotic misuse, antimicrobial stewardship programs (ASPs) are now a mandatory entity in all US hospitals. ASPs can use technological advances, such as the electronic medical record and clinical decision support systems, to impact a larger patient population with more efficiency. Additionally, through the use of mobile applications and social media, ASPs can highlight and propagate educational information regarding antimicrobial utilization to patients and providers in a widespread and timely manner. In this article, the authors describe how technology can play an important role in antimicrobial stewardship.


Journal of Infection Prevention | 2018

Impact of an antimicrobial stewardship program on healthcare-associated Clostridium difficile rates at a community-based teaching hospital

Matthew A. Moffa; Thomas L. Walsh; Amy Tang; Derek N. Bremmer

We conducted a pre-intervention/post-intervention study to assess the rate of healthcare-associated Clostridium difficile infections (HA-CDI) before and after the implementation of an antimicrobial stewardship program (ASP). Upon implementation of our ASP, the usage of targeted antimicrobials, including ceftriaxone, clindamycin, fluoroquinolones and carbapenem antibiotics, were significantly reduced. There was also a significant reduction in HA-CDI/1000 patient-days following ASP implementation (0.84 vs. 0.28; P = 0.035).


Infection | 2018

Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report

Thomas L. Walsh; Holly R. Bean; Robert B. Kaplan

Neisseria cinerea is a commensal species capable of colonizing the upper respiratory tract of humans. Bacteremia associated with this organism is very uncommon, with only seven previous cases described. We report a case of Neisseria cinerea bacteremia in a patient maintained on indefinite eculizumab therapy. It is the eighth reported case of Neisseria cinerea bacteremia and represents the first case in a patient receiving eculizumab.


Clinical Infectious Diseases | 2018

Acute Exacerbations of Chronic Obstructive Pulmonary Disease With a Low Procalcitonin Concentration: Impact of Antibiotic Therapy

Derek N Bremmer; Matthew A. Moffa; Kiet Ma; Holly R. Bean; Joseph Snatchko; Tamara Trienski; Courtney Watson; Thomas L. Walsh

BACKGROUND Patients admitted with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) often are prescribed antibiotics. Studies have shown that the use of procalcitonin (PCT) to guide the decision to initiate antibiotic therapy in AECOPD has resulted in less antibiotic use and similar outcomes compared with standard of care. We evaluated patients with AECOPD and low PCT concentrations to determine whether antibiotic therapy was associated with improved outcomes. METHODS We retrospectively evaluated adult patients admitted with AECOPD who had a peak PCT concentration <0.25 µg/mL. Patients were evaluated based on their antibiotic exposure: ≤24 hours vs >24 hours. We also evaluated outcomes based upon the duration of azithromycin therapy: ≤24 hours vs >24 hours. The primary outcome was all-cause 30-day readmissions. Secondary outcomes included length of stay (LOS) and COPD-related 30-day readmissions. RESULTS One hundred sixty-one and 195 patients received ≤24 hours vs >24 hours of antibiotic therapy, respectively. The cohort with ≤24 hours of antibiotics had a shorter LOS (2.8 vs 3.7 days; P = .01). There were no differences in all-cause 30-day readmissions (15.5% vs 17.4%; P = .63) or COPD-related 30-day readmissions (11.2% vs 12.3%; P = .74). Additionally, patients receiving ≤24 hours of azithromycin had a shorter LOS (3.0 vs 3.8 days; P = .002) and there were no differences in all-cause 30-day readmissions (16.2% vs 17.1%; P = .82) or COPD-related 30-day readmissions (11.9% vs 11.6%; P = .94). CONCLUSIONS For adult patients hospitalized with nonsevere AECOPD and low PCT concentrations, antibiotic therapy beyond 24 hours did not improve outcomes.


Journal of General Internal Medicine | 2018

Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations

Derek N. Bremmer; Briana E. DiSilvio; Crystal Hammer; Moeezullah Beg; Swati Vishwanathan; Daniel Speredelozzi; Matthew A. Moffa; Kurt Hu; Rasha Abdulmassih; Jina Makadia; Rikinder Sandhu; Mouhib Naddour; Noreen H. Chan-Tompkins; Tamara Trienski; Courtney Watson; Terrence J. Obringer; Jim Kuzyck; Thomas L. Walsh


The American Journal of Medicine | 2017

Creeping Skin Lesions: Primary Cutaneous Cryptococcosis

Thomas L. Walsh; Nitin Bhanot; Monika Murillo; Jeffrey M. Uchin; Zaw Min


The American Journal of Medicine | 2017

Impact of Procalcitonin Guidance with an Educational Program on Management of Adults Hospitalized with Pneumonia

Thomas L. Walsh; Briana E. DiSilvio; Crystal Hammer; Moeezullah Beg; Swati Vishwanathan; Daniel Speredelozzi; Matthew A. Moffa; Kurt Hu; Rasha Abdulmassih; Jina Makadia; Rikinder Sandhu; Mouhib Naddour; Noreen H. Chan-Tompkins; Tamara Trienski; Courtney Watson; Terrence J. Obringer; Jim Kuzyck; Derek N. Bremmer


Infectious Diseases in Clinical Practice | 2017

Evaluation of Management of Uncomplicated Community-Acquired Pneumonia: A Retrospective Assessment

Thomas L. Walsh; Briana E. DiSilvio; Daniel Speredelozzi; Crystal Hammer; Kurt Hu; Rasha Abdulmassih; Jina Makadia; Rikinder Sandhu; Mouhib Naddour; Swati Vishwanathan; Noreen H. Chan-Tompkins; Tamara L. Trienski; Matthew A. Moffa; Derek N. Bremmer

Collaboration


Dive into the Thomas L. Walsh's collaboration.

Top Co-Authors

Avatar

Matthew A. Moffa

Allegheny General Hospital

View shared research outputs
Top Co-Authors

Avatar

Derek N. Bremmer

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Courtney Watson

Allegheny General Hospital

View shared research outputs
Top Co-Authors

Avatar

Rikinder Sandhu

Allegheny General Hospital

View shared research outputs
Top Co-Authors

Avatar

Tamara Trienski

Allegheny General Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Crystal Hammer

Allegheny General Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jina Makadia

Allegheny General Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge